» Articles » PMID: 27589689

Combining Radiomic Features with a MiRNA Classifier May Improve Prediction of Malignant Pathology for Pancreatic Intraductal Papillary Mucinous Neoplasms

Abstract

Intraductal papillary mucinous neoplasms (IPMNs) are pancreatic cancer precursors incidentally discovered by cross-sectional imaging. Consensus guidelines for IPMN management rely on standard radiologic features to predict pathology, but they lack accuracy. Using a retrospective cohort of 38 surgically-resected, pathologically-confirmed IPMNs (20 benign; 18 malignant) with preoperative computed tomography (CT) images and matched plasma-based 'miRNA genomic classifier (MGC)' data, we determined whether quantitative 'radiomic' CT features (+/- the MGC) can more accurately predict IPMN pathology than standard radiologic features 'high-risk' or 'worrisome' for malignancy. Logistic regression, principal component analyses, and cross-validation were used to examine associations. Sensitivity, specificity, positive and negative predictive value (PPV, NPV) were estimated. The MGC, 'high-risk,' and 'worrisome' radiologic features had area under the receiver operating characteristic curve (AUC) values of 0.83, 0.84, and 0.54, respectively. Fourteen radiomic features differentiated malignant from benign IPMNs (p<0.05) and collectively had an AUC=0.77. Combining radiomic features with the MGC revealed an AUC=0.92 and superior sensitivity (83%), specificity (89%), PPV (88%), and NPV (85%) than other models. Evaluation of uncertainty by 10-fold cross-validation retained an AUC>0.80 (0.87 (95% CI:0.84-0.89)). This proof-of-concept study suggests a noninvasive radiogenomic approach may more accurately predict IPMN pathology than 'worrisome' radiologic features considered in consensus guidelines.

Citing Articles

Multimodal data deep learning method for predicting symptomatic pneumonitis caused by lung cancer radiotherapy combined with immunotherapy.

Yang M, Ma J, Zhang C, Zhang L, Xu J, Liu S Front Immunol. 2025; 15():1492399.

PMID: 39845959 PMC: 11751032. DOI: 10.3389/fimmu.2024.1492399.


Advances for Managing Pancreatic Cystic Lesions: Integrating Imaging and AI Innovations.

Seyithanoglu D, Durak G, Keles E, Medetalibeyoglu A, Hong Z, Zhang Z Cancers (Basel). 2025; 16(24.

PMID: 39766167 PMC: 11674829. DOI: 10.3390/cancers16244268.


Radiomics advances in the evaluation of pancreatic cystic neoplasms.

Mao K, Ma C, Song B Heliyon. 2024; 10(3):e25535.

PMID: 38333791 PMC: 10850586. DOI: 10.1016/j.heliyon.2024.e25535.


Combining Low-Dose Computer-Tomography-Based Radiomics and Serum Metabolomics for Diagnosis of Malignant Nodules in Participants of Lung Cancer Screening Studies.

Zyla J, Marczyk M, Prazuch W, Sitkiewicz M, Durawa A, Jelitto M Biomolecules. 2024; 14(1).

PMID: 38254644 PMC: 10813699. DOI: 10.3390/biom14010044.


Improving Pancreatic Cyst Management: Artificial Intelligence-Powered Prediction of Advanced Neoplasms through Endoscopic Ultrasound-Guided Confocal Endomicroscopy.

Jiang J, Chao W, Cao T, Culp S, Napoleon B, El-Dika S Biomimetics (Basel). 2023; 8(6).

PMID: 37887627 PMC: 10604893. DOI: 10.3390/biomimetics8060496.


References
1.
Permuth-Wey J, Chen D, Fulp W, Yoder S, Zhang Y, Georgeades C . Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. Cancer Prev Res (Phila). 2015; 8(9):826-34. PMC: 4560649. DOI: 10.1158/1940-6207.CAPR-15-0094. View

2.
Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K . Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol. 2011; 22(4):796-802. DOI: 10.1007/s00330-011-2319-8. View

3.
Diehn M, Nardini C, Wang D, McGovern S, Jayaraman M, Liang Y . Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A. 2008; 105(13):5213-8. PMC: 2278224. DOI: 10.1073/pnas.0801279105. View

4.
Permuth-Wey J, Chen Y, Fisher K, McCarthy S, Qu X, Lloyd M . A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas. PLoS One. 2015; 10(1):e0116869. PMC: 4301643. DOI: 10.1371/journal.pone.0116869. View

5.
Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F . MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011; 108(9):3713-8. PMC: 3048155. DOI: 10.1073/pnas.1100048108. View